OraSure Technologies (NASDAQ:OSUR) Upgraded by StockNews.com to “Buy”

StockNews.com upgraded shares of OraSure Technologies (NASDAQ:OSUR) from a hold rating to a buy rating in a report issued on Friday.

Separately, Evercore ISI lifted their price objective on shares of OraSure Technologies from $4.50 to $5.00 and gave the stock an in-line rating in a research report on Wednesday, August 7th. Two analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of Moderate Buy and an average price target of $6.67.

OraSure Technologies Price Performance

OSUR stock opened at $4.09 on Friday. The company has a market capitalization of $302.49 million, a PE ratio of 13.63 and a beta of 0.05. OraSure Technologies has a 12 month low of $3.91 and a 12 month high of $8.45. The firm’s 50-day moving average is $4.30 and its 200 day moving average is $4.72.

OraSure Technologies (NASDAQ:OSUR) last posted its quarterly earnings results on Tuesday, August 6th. The medical instruments supplier reported $0.03 EPS for the quarter. The company had revenue of $54.34 million for the quarter, compared to the consensus estimate of $53.35 million. OraSure Technologies had a net margin of 9.88% and a return on equity of 9.15%. Sell-side analysts forecast that OraSure Technologies will post -0.11 EPS for the current fiscal year.

Institutional Trading of OraSure Technologies

Several institutional investors and hedge funds have recently bought and sold shares of OSUR. SG Americas Securities LLC acquired a new stake in OraSure Technologies during the 1st quarter valued at approximately $72,000. Mackenzie Financial Corp acquired a new stake in OraSure Technologies during the 2nd quarter valued at approximately $72,000. Tocqueville Asset Management L.P. increased its holdings in shares of OraSure Technologies by 20.0% during the 1st quarter. Tocqueville Asset Management L.P. now owns 15,089 shares of the medical instruments supplier’s stock valued at $93,000 after purchasing an additional 2,512 shares in the last quarter. Shikiar Asset Management Inc. purchased a new position in shares of OraSure Technologies during the 2nd quarter valued at approximately $96,000. Finally, SkyView Investment Advisors LLC increased its holdings in shares of OraSure Technologies by 100.0% during the 2nd quarter. SkyView Investment Advisors LLC now owns 24,000 shares of the medical instruments supplier’s stock valued at $102,000 after purchasing an additional 12,000 shares in the last quarter. 93.50% of the stock is currently owned by institutional investors and hedge funds.

OraSure Technologies Company Profile

OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company’s products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.